The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
35 | 49 | 51 | 73 |
Growth
|
23 | 31 | 99 | 13 |
Safety
|
41 | 69 | 40 | 29 |
Sentiment
|
57 | 50 | 73 | 70 |
|
18 | 44 | 93 | 40 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
83 | 85 | 88 | 61 |
Opinions Change
|
73 | 50 | 50 | 94 |
Pro Holdings
|
n/a | 49 | 83 | 55 |
Market Pulse
|
25 | 21 | 11 | 8 |
Sentiment
|
57 | 50 | 73 | 70 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
35 | 49 | 51 | 73 |
Growth
|
23 | 31 | 99 | 13 |
|
41 | 69 | 40 | 29 |
Combined
|
4 | 51 | 83 | 11 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
42 | 42 | 42 | 42 |
Price vs. Earnings (P/E)
|
9 | 15 | 33 | 62 |
Price vs. Book (P/B)
|
89 | 93 | 89 | 92 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
35 | 49 | 51 | 73 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
91 | 1 | 55 | 49 |
Profit Growth
|
18 | 4 | 91 | 33 |
Capital Growth
|
15 | 91 | 81 | 13 |
Stock Returns
|
33 | 75 | 95 | 41 |
Growth
|
23 | 31 | 99 | 13 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
62 | 74 | 46 | 38 |
Refinancing
|
41 | 65 | 49 | 43 |
Liquidity
|
29 | 29 | 31 | 34 |
|
41 | 69 | 40 | 29 |
Discover high‑ranked alternatives to Aquestive Therapeutics and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.